CHD

Featured Article

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

FOURIER Trial Data Questions: Are PCSK9 Inhibitors The Right Choice?

Results of the FOURIER trial, presented at the 2017 ACC Scientific Sessions, raise questions about the efficacy of PCSK9 inhibitors as long-term therapy for patients with atherosclerotic CVD.

Latest Features

Identifying At-Risk Patients Using Coronary Artery Calcium Scores

Identifying At-Risk Patients Using Coronary Artery Calcium Scores

Researchers argue that elevated coronary artery calcium scores increase the risk of adverse cardiovascular events even in young patients.

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Oxygen Therapy for Acute MI: Best Practice or Harmful Treatment?

Evidence is lacking to support oxygen therapy for acute myocardial infarction.

Coronary Heart Disease in HIV/AIDS: Confronting 2 Major Health Issues

Coronary Heart Disease in HIV/AIDS: Confronting 2 Major Health Issues

A review of cardiovascular disease burden, particularly coronary heart disease, in HIV/AIDS.

Reducing the Progression of Coronary Heart Disease With Estradiol

Reducing the Progression of Coronary Heart Disease With Estradiol

In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 Inhibitors: Breakthrough in LDL-C Reduction, But Comes at a Cost

PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.

Latest News

Risk Stratification Using Platelet Aggregation in Stable CAD

Risk Stratification Using Platelet Aggregation in Stable CAD

Platelet aggregation levels did not predict cardiovascular events in patients with stable coronary artery disease.

Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis

Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis

Individuals with psoriasis have a greater risk for noncalcified coronary plaque burden compared with healthy individuals and patients with hyperlipidemia.

Coronary Artery Disease and Serum Calcium Levels: Is There a Genetic Connection?

Coronary Artery Disease and Serum Calcium Levels: Is There a Genetic Connection?

A genetic predisposition to elevated serum calcium levels may increase the risk for coronary artery disease and myocardial infarction.

Two-Hour Postload Glucose Predicts CV Events Better Than Fasting Glucose, HbA1C

Two-Hour Postload Glucose Predicts CV Events Better Than Fasting Glucose, HbA1C

Two-hour postload glucose (2h-PG) may be a better predictor of cardiovascular events in patients with coronary artery disease.

Is Pravastatin Effective as Primary Prevention Against CHD Events in Elderly?

Is Pravastatin Effective as Primary Prevention Against CHD Events in Elderly?

No differences were observed between pravastatin and usual care for CHD events, cause-specific deaths, stroke, cancer, and combination fatal CHD or nonfatal MI.

Impaired Coronary Distensibility Index Linked to Adverse Childhood Experience, Increases MACE Risk

Impaired Coronary Distensibility Index Linked to Adverse Childhood Experience, Increases MACE Risk

Individuals with adverse childhood experience may be at greater risk for major adverse cardiovascular events.

Gluten Does Not Increase Coronary Heart Disease Risk in General Population

Gluten Does Not Increase Coronary Heart Disease Risk in General Population

A gluten-free diet is not recommended for individuals without celiac disease to prevent coronary heart disease.

Measuring Visceral Adipose Tissue With DXA to Predict Atherosclerotic CVD

Measuring Visceral Adipose Tissue With DXA to Predict Atherosclerotic CVD

Fourteen percent of study participants experienced incident athersclerotic cardiovascular disease events.

Gray Hair Predictive of Coronary Artery Disease in Men

Gray Hair Predictive of Coronary Artery Disease in Men

Hair whitening score, hypertension, and dyslipidemia were all independent predictors of atherosclerotic coronary artery disease.

CVD Risk Predicted By Fasting Pancreatic Polypeptide in Type 2 Diabetes

CVD Risk Predicted By Fasting Pancreatic Polypeptide in Type 2 Diabetes

Fasting pancreatic polypeptide may be a marker for macrovascular disease.

Sign Up for Free e-Newsletters